key: cord-0061364-9afjccqx
authors: nan
title: Benefits of COVID-19 Vaccine AstraZeneca outweigh risks of blood clots
date: 2021-03-27
journal: Reactions Weekly
DOI: 10.1007/s40278-021-93004-3
sha: 88baf116d090b79f47da7db021b3b7a90ef59505
doc_id: 61364
cord_uid: 9afjccqx

nan

The EMA Pharmacovigilance Risk Assessment Committee (PRAC) advises that the vaccine is not associated with an increase in the overall risk of thromboembolic events, and there is no problem related to specific batches of the vaccine. However, it may be associated with very rare cases of blood clots associated with thrombocytopenia, including cerebral venous sinus thrombosis (CVST).

Following vaccination with AZD-1222 in approximately 20 million people in the UK and the European Economic Area (EEA), the EMA reviewed seven reported cases of disseminated intravascular coagulation (DIC) and 18 cases of CVST. No causal link was found but a link with the vaccine was considered possible.

The Committee considered that the efficacy of the vaccine in preventing hospitalisation and death from COVID-19 outweighs the very rare likelihood of developing DIC or CVST. However, patients should be aware of this possibility and should seek immediate medical attention if they develop symptoms suggestive of blood clots.

Healthcare professionals are advised that cases of thrombosis and thrombocytopenia, including mesenteric vein or cerebral vein/cerebral venous sinus thrombosis, have been reported within 14 days after vaccination with COVID-19 Vaccine AstraZeneca. Although the EMA considers that the benefit-risk balance of the vaccine remains positive, and there is no association with thromboembolic disorders overall, it will take steps to update the summary of product characteristics and package leaflet with information on cases of DIC and CVST. Vaccinators should warn recipients to seek immediate medical attention for symptoms of thromboembolism, thrombocytopenia and cerebral blood clots.

After reviewing data on thromboembolic events and thrombocytopenia after vaccination in Europe with the AstraZeneca COVID-19 vaccine and vaccination in India with the AstraZeneca vaccine manufactured by Serum Institute of India [Covishield], the GACVS COVID-19 subcommittee concluded that available data do not suggest any overall increase in thromboembolic events such as deep venous thrombosis or pulmonary embolism following administration of AstraZeneca COVID-19 vaccines.

Although very rare and unique thromboembolic events in combination with thrombocytopenia, such as CVST, have been reported after vaccination in Europe, it is not certain that they have been caused by vaccination, says the subcommittee.

The GACVS subcommittee recommends that countries continue to monitor the safety of all COVID-19 vaccines and encourage reporting of suspected adverse events. It agrees with the EMA's plans to further investigate and monitor for these events.

After reviewing data from reported cases, hospital admission and records of general practitioners, the UK MHRA agreed that the available evidence does not suggest that blood clots in veins are caused by COVID-19 Vaccine AstraZeneca, and this was confirmed by the Commission on Human Medicines.

A detailed review of five UK cases of CSVT and thrombocytopenia is ongoing but has been reported in less than one in a million people to date, and an association with vaccine has not been established.

"Given the extremely rare rate of occurrence of these CSVT events among the 11 million people vaccinated, and as a link to the vaccine is unproven, the benefits of the vaccine in preventing COVID-19, with its associated risk of hospitalisation and death, continue to outweigh the risks of potential side effects," said Dr June Raine, MHRA Chief Executive.

"The independent COVID-19 Expert Working Group of the Commission on Human Medicines, together with leading haematologists, conducted a rigorous analysis of all available evidence regarding reports of blood clots (thromboembolic events) and COVID-19 Vaccine AstraZeneca . . . We have been closely reviewing all reports of blood clots in the vein (venous thromboembolism, or VTE) following vaccination. There is no evidence either that VTE is occurring more often in people who have received the vaccine than in people who have not, for either vaccine . . . However, we will continue to closely monitor the reports where cerebral sinus venous thrombosis has occurred in conjunction with lowered platelets to understand whether there is any potential association," said Professor Sir Munir Pirmohamed, Chair of the Commission on Human Medicines.

19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. Internet Document

WHO. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on safety signals related to the AstraZeneca COVID-19 vaccine. Internet Document

UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca. Internet Document

Adis © 2021 Springer Nature Switzerland AG. All rights reserved